Show Search Form
human indexable | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
published | |||||||||||
registered interest | |||||||||||
answer date | |||||||||||
date | |||||||||||
date tabled | |||||||||||
ddp created | |||||||||||
answering body |
|
||||||||||
question status | Tabled | ||||||||||
answering dept id | 17 | ||||||||||
answering dept short name | Health and Social Care | ||||||||||
answering dept sort name | Health and Social Care | ||||||||||
ddp modified |
|
||||||||||
hansard heading | Pneumococcal Diseases: Vaccination | ||||||||||
house id | 2 | ||||||||||
identifier | HL16160 | ||||||||||
legislature |
|
||||||||||
parliament number | 57 | ||||||||||
question first answered |
|
||||||||||
question text | To ask Her Majesty's Government, further to the Written Answers by Baroness Blackwood of North Oxford on 22 May (HL15599 and HL15600) and the Public Health England modelling on the estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales, presented at the 37th annual meeting of the European Society for Paediatric Infectious Diseases, how many additional (1) invasive pneumococcal disease cases, (2) pneumococcal community acquired pneumonia cases, and (3) deaths, they predict as a result of a change to a 1+1 vaccine schedule over the next five years. | ||||||||||
session |
|
||||||||||
session number | 1 | ||||||||||
tabling member printed |
|
||||||||||
title | House of Lords Tabled Parliamentary Question 2017/19 HL16160 | ||||||||||
type |
|
||||||||||
uin | HL16160 | ||||||||||
version | 1 | ||||||||||
written parliamentary question type | Ordinary | ||||||||||
answer |
|
||||||||||
creator |
|
||||||||||
publisher | 25277 | ||||||||||
tabling member |
|